## Ramazzini Days 2020





Carcinogenicity bioassay on Sprague-Dawley rats exposed from prenatal life until natural death to EMF generated by 1.8 GHz frequency

Daniele Mandrioli and Fiorella Belpoggi

Ramazzini Institute Bologna Italy

October 25th



## RFR: experimental project



All experiments started at the 12° day of pregnancy and continued life-span

|            |                            |  | State of the art *    |
|------------|----------------------------|--|-----------------------|
| Experiment | Number of animals<br>(M+F) | Treatment                                | Published (partially) |
| BT 1 CEMRF | 2,448                      | RFR 1.8 GHz                              |                       |
| BT 3 CEMRF | 617                        | RFR/MW 1.8 GHz<br>+ γ-radiation (0.1 Gy) | Ongoing               |
| TOTAL      | 3,065                      |  |                       |

# RFR: study design



ANIMAL MODEL



FREQUENCY OF SIGNAL MODULATION

STUDY GROUPS AND EXPOSURE

1800 MHz

I group: 50 V/m (202 F, 207 M)

II group: 25 V/m (202 F, 209 M)

III group: 5 V/m (410 F, 401 M)

IV group: 0 V/m (405 F, 412 M)

TIME OF EXPOSURE

continuous exposure 19 hours/day, 7 days/week

## RFR: exposure system





To expose the animals to a mobile phone radiofrequency field representative of a 1.8 GHz base station, a specific radiation system, totally representative of the real environmental situation present in geographic areas close to GSM base station radiation emissions

### RFR: brain and heart results




#### Heart

Statistically significant increase in malignant Schwannoma in males at the highest dose (50 V/m). Increase in Schwann cell hyperplasia in exposed male and female rats.

#### • Brain

Slight non-statistically significant dose-related increase in malignant glioma in exposed female rats



# **RFR: Total Benign Tumors**



| Group | Dose           | Animals |     |     | Benign tumours |      |         |  |
|-------|----------------|---------|-----|-----|----------------|------|---------|--|
| No.   | EMF-GSM 1.8GHz |         |     |     | ır-bearing     | Tu   | mours   |  |
|       | (V/m)          |         |     | an  | animals        |      |         |  |
|       |                | Sex     | No. | No. | %              | No.  | Per 100 |  |
|       |                |         |     |     |                |      | animals |  |
|       |                |         |     |     |                |      |         |  |
| I     | 0              | М       | 412 | 267 | 64.8           | 368  | 89.3    |  |
|       | (control)      | F       | 405 | 328 | 81.0           | 783  | 193.3   |  |
|       |                | M+F     | 817 | 595 | 72.8           | 1151 | 140.9   |  |
|       |                |         |     |     |                |      |         |  |
| II    | 5              | М       | 401 | 213 | 53.3           | 304  | 76.0    |  |
|       |                | F       | 410 | 300 | 73.2           | 655  | 159.8   |  |
|       |                | M+F     | 811 | 513 | 63.3           | 959  | 118.2   |  |
|       |                |         |     |     |                |      |         |  |
| III   | 25             | М       | 209 | 123 | 58.9           | 182  | 87.1    |  |
|       |                | F       | 202 | 152 | 75.2           | 330  | 163.4   |  |
|       |                | M+F     | 411 | 275 | 66.9           | 512  | 124.6   |  |
|       |                |         |     |     |                |      |         |  |
| IV    | 50             | М       | 207 | 132 | 63.8           | 186  | 89.9    |  |
|       |                | F       | 202 | 149 | 73.8           | 359  | 177.7   |  |
|       |                | M+F     | 409 | 281 | 68.7           | 545  | 133.3   |  |
|       |                |         |     |     |                |      |         |  |

# **RFR: Total Malignant Tumors**



| Group | Dose           | Animals |     |         | Malignant tumours |     |         |  |
|-------|----------------|---------|-----|---------|-------------------|-----|---------|--|
| No.   | EMF-GSM 1.8GHz |         |     | Tumou   | Tumour-bearing    |     | Tumours |  |
|       | (V/m)          |         |     | animals |                   |     |         |  |
|       |                | Sex     | No. | No.     | %                 | No. | Per 100 |  |
|       |                |         |     |         |                   |     | animals |  |
|       |                |         |     |         |                   |     |         |  |
| I     | 0              | M       | 412 | 122     | 29.6              | 134 | 32.5    |  |
|       | (control)      | F       | 405 | 176     | 43.5              | 218 | 53.8    |  |
|       |                | M+F     | 817 | 299     | 36.6              | 354 | 43.3    |  |
|       |                |         |     |         |                   |     |         |  |
| П     | 5              | M       | 401 | 128     | 32.0              | 138 | 34.5    |  |
|       |                | F       | 410 | 180     | 43.9              | 225 | 54.9    |  |
|       |                | M+F     | 811 | 308     | 38.0              | 363 | 44.8    |  |
|       |                |         |     |         |                   |     |         |  |
| III   | 25             | М       | 209 | 47      | 22.5              | 50  | 23.9    |  |
|       |                | F       | 202 | 93      | 46.0              | 118 | 58.4    |  |
|       |                | M+F     | 411 | 140     | 34.1              | 168 | 40.9    |  |
|       |                |         |     |         |                   |     |         |  |
| IV    | 50             | М       | 207 | 68      | 32.9              | 82  | 39.6    |  |
|       |                | F       | 202 | 85      | 42.1              | 107 | 53.0    |  |
|       |                | M+F     | 409 | 153     | 37.4              | 189 | 46.2    |  |
|       |                |         |     |         |                   |     |         |  |

#### RFR: characterization of lymphoma and leukemia

#### All the cases reviewed based on:

- 1) Updated pathological morphology criteria (HE staining) as indicated in a new international classification INHAND shared by pathologists from STP, ESTP, BSTP and JSTP
- 2) IHC analysis for the identification of the tumour cell lineage (i.e. B-cell /PAX5/CD20, T-cell/CD3/CD4, lymphoblastic cells/TdT) and for the evaluation of the degree of neoplastic cell proliferation (Ki67).




### **Immunoblastic lymphoma**

Primary site: lung;

other organs involved: none;

type: B-cells;

<u>histotype</u>: immunoblastic lymphoma (PAX5 +, TdT +, CD3 -)



### RFR: state-of-the-art



- Morphological analysis (H&E) completed for total tumors at all dose groups for BT1CEMRF. Identification and molecular characterization of lymphoma and leukemia is currently ongoing for BT1CEMRF.
- Statistical evaluation of neoplastic lesions and developmental parameters is currently ongoing for BT1CEMRF.
- Ongoing histopathological evaluation for BT3CEMRF.

# Thank you!



